Merck & Co., Inc. (MRK)
NYSE: MRK · IEX Real-Time Price · USD
129.03
-0.19 (-0.15%)
May 2, 2024, 9:35 AM EDT - Market open
Merck & Co. Employees
Merck & Co. had 72,000 employees on December 31, 2023. The number of employees increased by 3,000 or 4.35% compared to the previous year.
Employees
72,000
Change (1Y)
3,000
Growth (1Y)
4.35%
Revenue / Employee
$834,931
Profits / Employee
$5,069
Market Cap
326.20B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
Dec 31, 2018 | 69,000 | 0 | - |
Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
Dec 31, 2016 | 68,000 | 0 | - |
Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
MRK News
- 1 day ago - Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - Business Wire
- 1 day ago - Is Merck Stock Fully Valued At $130? - Forbes
- 2 days ago - Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults - Business Wire
- 6 days ago - Merck's Cancer Drug and Vaccine Sales Drive Better-Than-Expected Results - Investopedia
- 7 days ago - Merck raises 2024 profit forecast on strong cancer, HPV drugs sales - Reuters
- 7 days ago - Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales - CNBC
- 7 days ago - Merck's first-quarter results beat expectations amid healthy vaccine-sales growth - Market Watch
- 7 days ago - Merck Announces First-Quarter 2024 Financial Results - Business Wire